Physician profile
William E Prater
NPI 1700956539
$369.11
in general payments reported to CMS, 2019-2025
9 companies · $43.73 in 2025
The $43.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.41 · 2020: $39.93 · 2021: $98.29 · 2022: $42.39 · 2023: $44.60 · 2024: $72.76 · 2025: $43.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $75.31 | 2020-2024 | Breztri |
| Biohaven Pharmaceuticals, INC. | $55.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $52.30 | 2019-2021 | |
| Lilly USA, LLC | $46.66 | 2020-2024 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $43.42 | 2023-2024 | Nuedexta, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.19 | 2021 | |
| Mallinckrodt Hospital Products INC. | $26.33 | 2025 | Terlivaz |
| Novo Nordisk INC | $22.14 | 2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $17.40 | 2025 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Prater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.